Human catechol-O-methyltransferase down-regulation by estradiol

被引:148
作者
Jiang, H
Xie, T
Ramsden, DB
Ho, SL [1 ]
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Med, Div Neurol, Hong Kong, Hong Kong, Peoples R China
[2] Univ Birmingham, Dept Med, Birmingham B15 2TT, W Midlands, England
关键词
catechol-O-methyltransferase; estrogen receptor; estrogen response element; S-adenosyl-L-methionine; 17; beta-estradiol; Parkinson's disease; dopamine;
D O I
10.1016/S0028-3908(03)00286-7
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Catechol-O-methyltransferase (COMT) is a crucial enzyme in dopamine and levodopa metabolism. Previously we reported that physiological concentrations of 17beta-estradiol (E2) down-regulated steady-state 1.3-kb COMT mRNA levels in MCF-7 cells. In this study, we investigated whether similar reductions occurred in a glial cell line (U138MG) and whether COMT protein and activity levels paralleled the reduction in COMT mRNA levels in MCF-7 cells. In addition, we explored the mechanism of E2 action. E2 had no effect on COMT mRNA levels in U138MG cells, but significantly reduced COMT protein and activity in MCF-7 cells (activity by 53% at 10(-7) M of E2, by 45% at 10(-8) M, and by 28% at 10(-9) M relative to non-E2-treated cells). A specific estrogen receptor antagonist (ICI 182780) blocked these estrogenic effects. Estrogen receptor in nuclear extracts of MCF-7 cells, which were pretreated with E2 (10(-9) M) for 48 h, bound to the whole proximal and distal promoter regions, as determined by electrophoretic mobility shift analysis (EMSA). We propose that E2 decreased COMT activity through down-regulation of its gene and protein expression mediated via ER interaction with response elements in the promoter region of the gene. Our findings may explain the lower of COMT activity in women compared to that in men, and, in part, the beneficial effects of E2 therapy in post-menopausal Parkinson's disease patients. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1011 / 1018
页数:8
相关论文
共 33 条
[1]   Estradiol repression of tumor necrosis factor-α transcription requires estrogen receptor activation function-2 and is enhanced by coactivators [J].
An, JP ;
Ribeiro, RCJ ;
Webb, P ;
Gustafsson, JÅ ;
Kushner, PJ ;
Baxter, JD ;
Leitman, DC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (26) :15161-15166
[2]   HUMAN LIVER CATECHOL-O-METHYLTRANSFERASE PHARMACOGENETICS [J].
BOUDIKOVA, B ;
SZUMLANSKI, C ;
MAIDAK, B ;
WEINSHILBOUM, R .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 48 (04) :381-389
[3]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[4]   Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells [J].
Cariou, S ;
Donovan, JCH ;
Flanagan, WM ;
Milic, A ;
Bhattacharya, N ;
Slingerland, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (16) :9042-9046
[5]   The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells [J].
Diel, P ;
Smolnikar, K ;
Michna, H .
BREAST CANCER RESEARCH AND TREATMENT, 1999, 58 (02) :87-97
[6]   ANTIUTEROTROPHIC EFFECTS OF THE PURE ANTIESTROGEN ICI 182,780 IN ADULT FEMALE MONKEYS (MACACA-NEMESTRINA) - QUANTITATIVE MAGNETIC-RESONANCE-IMAGING [J].
DUKES, M ;
WATERTON, JC ;
WAKELING, AE .
JOURNAL OF ENDOCRINOLOGY, 1993, 138 (02) :203-&
[7]   ANTIUTEROTROPHIC EFFECTS OF A PURE ANTIESTROGEN, ICI 182,780 - MAGNETIC-RESONANCE-IMAGING OF THE UTERUS IN OVARIECTOMIZED MONKEYS [J].
DUKES, M ;
MILLER, D ;
WAKELING, AE ;
WATERTON, JC .
JOURNAL OF ENDOCRINOLOGY, 1992, 135 (02) :239-&
[8]  
FAHNDRICH E, 1980, ACTA PSYCHIAT SCAND, V61, P427
[9]   Trafficking of nuclear receptors in living cells [J].
Hager, GL ;
Lim, CS ;
Elbi, C ;
Baumann, CT .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2000, 74 (05) :249-254
[10]   Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose [J].
Heikkinen, H ;
Varhe, A ;
Laine, T ;
Puttonen, J ;
Kela, M ;
Kaakkola, S ;
Reinikainen, K .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (04) :363-371